Grades 3 to 4 laboratory abnormalities
| . | First 12 mo, grade 3/4, %, n = 532 . | After 12 mo, grade 3/4, %, n = 484 . | Overall, grade 3/4, %, n = 532 . |
|---|---|---|---|
| Hematology parameters | |||
| Neutropenia | 33 | 13 | 36 |
| Thrombocytopenia | 18 | 9 | 22 |
| Anemia | 6 | 4 | 8 |
| Biochemistry parameters | |||
| ALT/AST increase | 2 | 1 | 3 |
| . | First 12 mo, grade 3/4, %, n = 532 . | After 12 mo, grade 3/4, %, n = 484 . | Overall, grade 3/4, %, n = 532 . |
|---|---|---|---|
| Hematology parameters | |||
| Neutropenia | 33 | 13 | 36 |
| Thrombocytopenia | 18 | 9 | 22 |
| Anemia | 6 | 4 | 8 |
| Biochemistry parameters | |||
| ALT/AST increase | 2 | 1 | 3 |
Safety data as per July 31, 2002, based on 532 patients; events after 12 months based on 484 patients still on imatinib after 12 months. After July 31, 2002, the following SAEs related to myelosuppression were reported: neutropenia less than 1%; thrombocytopenia less than 1%; and anemia 2%.
ALT indicates alanine aminotransferase; and AST, aspartate aminotransferase.